Status:
COMPLETED
Vaginal Estradiol Tablets (Vagifem®) and Endometrial Cancer Risk in the Treatment of Postmenopausal Vaginal Atrophy
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Postmenopausal Vaginal Atrophy
Eligibility:
FEMALE
50-75 years
Brief Summary
The study will include data from a nationwide Danish cohort of postmenopausal women and the United States of America (US) cohort of postmenopausal women. The Danish nationwide cohort will be establish...
Eligibility Criteria
Inclusion
- Female
- Age 50-75 years at entry
Exclusion
- Endometrial cancer prior to entry
- Any use of vaginal estrogen products prior to entry
- Hysterectomy prior to entry
Key Trial Info
Start Date :
January 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2022
Estimated Enrollment :
500000 Patients enrolled
Trial Details
Trial ID
NCT05243823
Start Date
January 15 2022
End Date
July 31 2022
Last Update
December 23 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Soeborg, Denmark